Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy

O. Kucuk, F. H. Sarkar, W. Sakr, Z. Djuric, M. N. Pollak, F. Khachik, Y. W. Li, M. Banerjee, David Grignon, J. S. Bertram, J. D. Crissman, E. J. Pontes, Jr Wood D.P.

Research output: Contribution to journalArticle

320 Citations (Scopus)

Abstract

An inverse association has been observed between dietary intake of lycopene and the risk of prostate cancer. We investigated the effects of lycopene supplementation in patients with prostate cancer. Twenty-six men with newly diagnosed, clinically localized (14 T1 and 12 T2) prostate cancer were randomly assigned to receive 15 mg of lycopene (n = 15) twice daily or no supplementation (n = 11) for 3 weeks before radical prostatectomy. Biomarkers of differentiation and apoptosis were assessed by Western blot analysis on benign and malignant parts of the prostate gland. Prostatectomy specimens were entirely embedded, step-sectioned, and evaluated for pathological stage, Gleason score, volume of cancer, and extent of high-grade prostatic intraepithelial neoplasia. Plasma levels of lycopene, insulin-like growth factor-1 (IGF-1), IGF binding protein-3, and prostate-specific antigen were measured at baseline and after 3 weeks of supplementation or observation. Eleven (73%) subjects in the intervention group and two (18%) subjects in the control group had no involvement of surgical margins and/or extra-prostatic tissues with cancer (P = 0.02). Twelve (84%) subjects in the lycopene group and five (45%) subjects in the control group had tumors

Original languageEnglish (US)
Pages (from-to)861-868
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume10
Issue number8
StatePublished - 2001
Externally publishedYes

Fingerprint

Phase II Clinical Trials
Prostatectomy
Randomized Controlled Trials
Prostatic Neoplasms
Prostatic Intraepithelial Neoplasia
Neoplasms
Control Groups
Insulin-Like Growth Factor Binding Protein 3
Neoplasm Grading
Somatomedins
Prostate-Specific Antigen
Prostate
Biomarkers
Western Blotting
Observation
lycopene
Apoptosis

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Kucuk, O., Sarkar, F. H., Sakr, W., Djuric, Z., Pollak, M. N., Khachik, F., ... Wood D.P., J. (2001). Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiology Biomarkers and Prevention, 10(8), 861-868.

Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. / Kucuk, O.; Sarkar, F. H.; Sakr, W.; Djuric, Z.; Pollak, M. N.; Khachik, F.; Li, Y. W.; Banerjee, M.; Grignon, David; Bertram, J. S.; Crissman, J. D.; Pontes, E. J.; Wood D.P., Jr.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 10, No. 8, 2001, p. 861-868.

Research output: Contribution to journalArticle

Kucuk, O, Sarkar, FH, Sakr, W, Djuric, Z, Pollak, MN, Khachik, F, Li, YW, Banerjee, M, Grignon, D, Bertram, JS, Crissman, JD, Pontes, EJ & Wood D.P., J 2001, 'Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy', Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 8, pp. 861-868.
Kucuk, O. ; Sarkar, F. H. ; Sakr, W. ; Djuric, Z. ; Pollak, M. N. ; Khachik, F. ; Li, Y. W. ; Banerjee, M. ; Grignon, David ; Bertram, J. S. ; Crissman, J. D. ; Pontes, E. J. ; Wood D.P., Jr. / Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. In: Cancer Epidemiology Biomarkers and Prevention. 2001 ; Vol. 10, No. 8. pp. 861-868.
@article{8637b51664b848f297276b2d0c8dfcef,
title = "Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy",
abstract = "An inverse association has been observed between dietary intake of lycopene and the risk of prostate cancer. We investigated the effects of lycopene supplementation in patients with prostate cancer. Twenty-six men with newly diagnosed, clinically localized (14 T1 and 12 T2) prostate cancer were randomly assigned to receive 15 mg of lycopene (n = 15) twice daily or no supplementation (n = 11) for 3 weeks before radical prostatectomy. Biomarkers of differentiation and apoptosis were assessed by Western blot analysis on benign and malignant parts of the prostate gland. Prostatectomy specimens were entirely embedded, step-sectioned, and evaluated for pathological stage, Gleason score, volume of cancer, and extent of high-grade prostatic intraepithelial neoplasia. Plasma levels of lycopene, insulin-like growth factor-1 (IGF-1), IGF binding protein-3, and prostate-specific antigen were measured at baseline and after 3 weeks of supplementation or observation. Eleven (73{\%}) subjects in the intervention group and two (18{\%}) subjects in the control group had no involvement of surgical margins and/or extra-prostatic tissues with cancer (P = 0.02). Twelve (84{\%}) subjects in the lycopene group and five (45{\%}) subjects in the control group had tumors",
author = "O. Kucuk and Sarkar, {F. H.} and W. Sakr and Z. Djuric and Pollak, {M. N.} and F. Khachik and Li, {Y. W.} and M. Banerjee and David Grignon and Bertram, {J. S.} and Crissman, {J. D.} and Pontes, {E. J.} and {Wood D.P.}, Jr",
year = "2001",
language = "English (US)",
volume = "10",
pages = "861--868",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy

AU - Kucuk, O.

AU - Sarkar, F. H.

AU - Sakr, W.

AU - Djuric, Z.

AU - Pollak, M. N.

AU - Khachik, F.

AU - Li, Y. W.

AU - Banerjee, M.

AU - Grignon, David

AU - Bertram, J. S.

AU - Crissman, J. D.

AU - Pontes, E. J.

AU - Wood D.P., Jr

PY - 2001

Y1 - 2001

N2 - An inverse association has been observed between dietary intake of lycopene and the risk of prostate cancer. We investigated the effects of lycopene supplementation in patients with prostate cancer. Twenty-six men with newly diagnosed, clinically localized (14 T1 and 12 T2) prostate cancer were randomly assigned to receive 15 mg of lycopene (n = 15) twice daily or no supplementation (n = 11) for 3 weeks before radical prostatectomy. Biomarkers of differentiation and apoptosis were assessed by Western blot analysis on benign and malignant parts of the prostate gland. Prostatectomy specimens were entirely embedded, step-sectioned, and evaluated for pathological stage, Gleason score, volume of cancer, and extent of high-grade prostatic intraepithelial neoplasia. Plasma levels of lycopene, insulin-like growth factor-1 (IGF-1), IGF binding protein-3, and prostate-specific antigen were measured at baseline and after 3 weeks of supplementation or observation. Eleven (73%) subjects in the intervention group and two (18%) subjects in the control group had no involvement of surgical margins and/or extra-prostatic tissues with cancer (P = 0.02). Twelve (84%) subjects in the lycopene group and five (45%) subjects in the control group had tumors

AB - An inverse association has been observed between dietary intake of lycopene and the risk of prostate cancer. We investigated the effects of lycopene supplementation in patients with prostate cancer. Twenty-six men with newly diagnosed, clinically localized (14 T1 and 12 T2) prostate cancer were randomly assigned to receive 15 mg of lycopene (n = 15) twice daily or no supplementation (n = 11) for 3 weeks before radical prostatectomy. Biomarkers of differentiation and apoptosis were assessed by Western blot analysis on benign and malignant parts of the prostate gland. Prostatectomy specimens were entirely embedded, step-sectioned, and evaluated for pathological stage, Gleason score, volume of cancer, and extent of high-grade prostatic intraepithelial neoplasia. Plasma levels of lycopene, insulin-like growth factor-1 (IGF-1), IGF binding protein-3, and prostate-specific antigen were measured at baseline and after 3 weeks of supplementation or observation. Eleven (73%) subjects in the intervention group and two (18%) subjects in the control group had no involvement of surgical margins and/or extra-prostatic tissues with cancer (P = 0.02). Twelve (84%) subjects in the lycopene group and five (45%) subjects in the control group had tumors

UR - http://www.scopus.com/inward/record.url?scp=0034906966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034906966&partnerID=8YFLogxK

M3 - Article

C2 - 11489752

AN - SCOPUS:0034906966

VL - 10

SP - 861

EP - 868

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 8

ER -